neg impact lyrica loe expect
downgrad rate hold downgrad
tp tp base
forward price-to-earnings multipl estim non-gaap ep
provid upsid potenti
estim base follow factor neg
impact lyrica loe agreement
gsk creat new consum healthcar joint ventur
lower sale legaci establish product steril
recommend hold rate due stagnant
growth near futur continu expect neg
impact lyrica loe therefor
expect flat revenu growth growth
innov health segment grew oper led
strength key brand ibranc grew grew
revenu xeljanz revenu grew due growth
ra well new indic expect contribut
eliqui revenu grew
net incom declin adjust
net incom increas ep
decreas adjust ep increas
adjust ep in-lin
estim
mn except ep crispidea name inc tickerpfestock ratingholddowngradeindustri viewoverweightpositivepric apr week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha inc april
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
decemb enter
definit agreement gsk two
compani agre creat new consum healthcar
joint ventur oper global gsk
consum healthcar name exchang contribut
consum healthcar busi receiv equiti
stake new compani gsk remain
new compani
revenu increas
in-lin estim saw
continu growth sever biggest-sel medicin
vaccin emerg market biosimilar
revenu growth partial off-set loe
impact well decreas legaci establish
product portfolio develop market steril
inject portfolio due continu legaci hospira product
shortag
essenti health segment growth emerg market
biosimilar off-set lower revenu
legaci establish product portfolio develop market
product suppli shortag steril inject busi
current price-to-earnings ratio fallen
due declin stock price
quarter price-to-earnings shown huge fluctuat past
due unsustain earn
expect forward price-to-earnings
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date jan last split factor new per last split date jul inform pfizer inc april
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net incom continu net incom discontinu prefer net incom avail common weight averag share estim annual actual annual actual quarterli inc april
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru expenses- defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item pfizer inc april
net cash provid oper activ compar
decreas net cash provid oper activ reflect decreas net cash gener
net cash provid invest activ compar net cash use
invest activ chang net cash use invest activ attribut
increas net proce gener sale invest cash need
decreas cash use acquisit net cash acquir due acquisit
develop commerci right astrazeneca small molecul anti-infect busi
substanti remain consider mediv acquisit
net cash use financ activ compar
increas net cash use financ activ attribut less proce rais
short-term borrow higher purchas common stock
incom statement item total gross research develop sell gener administr sg oper depreciation- oper profit interest incom special interest incom minor incom incom net incom outstand dilut ep dilut ep dividend paid per share actual annual estim annual actual quarterli inc april
pfizer perform led continu growth sever import
medicin vaccin emerg market biosimilar
pfizer revenu increas compar
oper growth unfavor impact
foreign exchang quarter
sale decreas compar
adjust cost sale decreas compar
sale revenu
compar
si expens declin compar
adjust si expens decreas
compar
 expens increas compar
adjust expens increas
compar
increas
compar
compar
deduct compar
adjust deduct declin compar
adjust effect tax rate
compar
pfizer effect tax rate unfavor impact non-recurr
tax benefit record reflect decemb
enact tax cut job act tcja
net loss compar net incom
adjust incom increas compar
ep compar
adjust ep increas
compar
pfizer revenu increas compar
reflect oper growth total revenu
 decreas compar
total intern revenu decreas compar
emerg market revenu increas compar
reflect oper increas foreign
exchang unfavor impact emerg market revenu
oper increas emerg market led eh segment
primarili legaci establish product portfolio steril inject
pharmaceut portfolio well prevenar ibranc eliqui ih
sale compar
sale revenu compar
sale increas rel flat compar
due
increas sale volum relat key product within product portfolio
increas
compar
compar
higher cost across sip portfolio result complex high
qualiti product manufactur across legaci hospira plant
partial off-set decreas cost across variou market
increas royalti expens base mix product sold
unfavor impact hedg activ inter-company inventori
si expens increas compar
adjust si expens increas
compar si expens revenu
compar
si expens decreas due lower advertis promot field forc
expens well gener administr expens reflect benefit
cost-reduct product initi non-recurr
charit contribut pfizer foundat decreas invest across
sever key product viagra enbrel lower healthcar reform
expens result true prior year amount
 expens increas compar
adjust expens increas compar
 expens revenu
compar
 expens increas due
increas cost associ phase clinic trial relat
inhibitor initi decemb difficil
vaccin program initi march well increas
spend valent pneumococc conjug vaccin candid
increas cost associ bavencio program
increas valu portfolio perform share grant reflect
chang price common stock well manag
assess probabl specifi perform criteria
amort intang asset increas
compar amort intang asset increas
due amort expens pre-tax associ
approv xtandi treatment non-metastat castration-
resist prostat cancer approv result transfer
indefinite-liv ipr intang asset finite-liv
compar
amort
increas
compar
restructur charg compar
deduct increas compar
adjust incom increas
compar
effect tax rate compar
higher effect tax rate due non-recurr tax benefit
record reflect enact tcja adjust tax rate
compar
net incom decreas compar
adjust net incom increas compar
ep decreas compar
adjust ep increas compar
gaap ep decreas
compar
increas
compar
manag commerci oper two distinct busi
pfizer innov health ih pfizer essenti health eh
increas
compar
innov segment revenu increas
compar total revenu increas
compar
ih revenu increas oper due continu
growth key brand includ eliqui ibranc xeljanz prevnar
total revenu ih segment increas
compar total intern revenu
increas compar
total revenu increas
compar total revenu decreas
compar
total revenu increas
compar total intern revenu increas
compar
total revenu
increas
compar
world-wide growth led intern oper growth
due higher volum pediatr indic result
launch china increas order associ gavi vaccin
allianc partial off-set lower birth cohort volum certain
growth due pediatr indic partial
off-set continu declin revenu adult indic due
high initi captur rate elig popul follow success
launch result smaller remain catch
total revenu ibranc increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
world-wide oper growth reflect continu uptak
intern market mostli driven develop europ japan select
emerg market launch secur access reimburs
well non-recurr one-tim price
adjust relat final reimburs agreement
growth due continu demand growth
partial off-set uptak competitor increas rebat ibranc
maintain class leadership among cyclin-depend kinas inhibitor
major market support scientific/clin data continu
total revenu eliqui increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
world-wide oper growth led continu increas
adopt non-valvular atrial fibril well oral anti-coagul
total revenu
ibranc increas
compar
total revenu
eliqui increas
compar
total revenu xeljanz increas
compar total revenu increas
compar
total revenu increas
compar revenu increas
compar
growth led increas adopt among
rheumatologist grow awar among patient improv
payer access lesser extent launch indic
ulcer coliti indic
oper growth intern led
approv ra indic certain european market well
continu uptak japan canada emerg market
total revenu
xeljanz increas
compar
total revenu
enbrel decreas
compar
total revenu enbrel decreas
compar total revenu decreas
compar
world-wide oper declin due on-going biosimilar
competit develop europ market expect
total revenu xtandi increas
compar total revenu increas
compar
total revenu lyrica decreas
compar total revenu increas
compar
total revenu increas
compar total intern revenu decreas
compar
total revenu essenti health segment decreas
compar total revenu
decreas compar
total revenu decreas
compar total intern revenu increas
compar
eh revenu declin oper neg impact
oper declin legaci establish product lep portfolio
develop market driven industry-wid price challeng
gener competit
oper declin steril inject pharmaceut sip
portfolio develop market due increas competit across
portfolio continu legaci hospira product shortag
oper declin peri-lo product portfolio develop
market primarili due expect declin lyrica develop europ
pristiq partial off-set addit viagra revenu
canada previous record ih busi
total revenu
lyrica decreas
compar
total revenu
decreas
compar
total revenu lyrica decreas
compar total revenu decreas
compar
total revenu increas
compar total intern revenu decreas
compar
oper declin world-wide lyrica revenu driven
loss exclus develop europ market australia partial
off-set growth growth oral dissolv tablet
formul japan
total revenu lipitor increas compar
total revenu decreas
compar
total revenu decreas
compar total intern revenu increas
compar
world-wide oper growth driven increas demand
china partial off-set price pressur china non-recurr
favor rebat occur gener competit
total revenu decreas compar
total revenu decreas
compar
total revenu
lyrica decreas
compar
compar
decemb merck kgaa darmstadt germani merck kgaa
announc data plan interim analysi phase
javelin ovarian studi avelumab support studi initi
hypothesi therefor allianc made decis termin
trial align independ data monitor committe dmc
top-lin result show studi evalu avelumab
combin and/or follow platinum base chemotherapi
previous untreat patient ovarian cancer would achiev
superior pre-specifi primari endpoint progression-fre surviv
novemb merck kgaa announc phase
javelin ovarian trial evalu avelumab alon combin
pegyl liposom doxorubicin type chemotherapi compar
meet pre-specifi primari endpoint overal surviv
os patient platinum-resist -refractori ovarian cancer
new safeti signal observ avelumab alon combin
safeti profil avelumab trial consist
observ overal javelin clinic develop program data
current analyz detail result share
novemb announc fda approv daurismo
once-daili oral medicin treatment newly-diagnos acut
myeloid leukemia adult patient year older
comorbid preclud use intens induct chemotherapi
announc
data plan
interim analysi
studi avelumab
support
therefor
allianc made
decis termin
trial align
independ data
announc fda
exclus lyrica
grant extend period
 market exclus
lyrica
addit six month
novemb announc fda approv lorbrena third
gener anaplast lymphoma kinas tyrosin kinas inhibitor
patient alk-posit metastat non-smal cell lung cancer nsclc
whose diseas progress crizotinib least one
inhibitor metastat diseas whose diseas progress alectinib
ceritinib first inhibitor therapi metastat diseas
indic approv acceler approv base tumor
respons rate durat respons continu approv indic
may conting upon verif descript clinic benefit
novemb announc fda grant pediatr
exclus lyrica grant extend period market exclus
lyrica addit six month june pediatr
exclus determin base data lyrica pediatr epilepsi
program submit respons fda written request
evalu use lyrica adjunct therapi partial onset
seizur pediatr epilepsi patient also requir post-
decemb astella pharma inc astella announc
phase arch trial evalu xtandi plu androgen depriv therapi
men metastat hormone-sensit prostat cancer met
surviv versu alon preliminari safeti analysi arch trial
appear consist safeti profil xtandi previou clinic trial
announc
american societi
meet
safeti efficaci studi
versu
rituximab-eu met
primari endpoint
orr week
decemb announc american societi hematolog
annual meet reflect studi compar safeti
efficaci studi versu rituxan/mabthera rituximab-
eu met primari endpoint overal respons rate orr week
studi
data on-going reflect studi
demonstr clinic meaning differ efficaci
term orr week mabthera
first-lin treatment patient low tumor burden
orr week compar rituximab-
eu within pre-specifi equival margin addit estim
rate one-year similar across group vs pf-
mabthera group respect result also show
similar safeti profil mabthera
decemb announc phase trial strive
staphylococcu aureu surgic inpati vaccin efficaci evalu
vaccin discontinu due futil decis base
recommend independ dmc compos extern expert
conduct pre-plan interim analysi
dmc conclud data studi reach futil mean
low statist probabl studi meet pre-defin
primari efficaci object adult undergo elect spinal fusion surgeri
complet plan phase expans studi safeti review
dmc indic investig vaccin safe well
januari fda
accept review
applic pf-
biosimilar humira
act goal date
decis fda
januari fda accept review biolog licens applic
propos biosimilar humira biosimilar user fee
act goal date decis fda
decemb announc committe medicin
product human use european medicin agenc adopt
posit opinion recommend market author zirabev pf-
propos biosimilar avastin
decemb announc initi phase program
pneumococc conjug vaccin candid pf-
prevent invas diseas pneumonia caus
streptococcu pneumonia serotyp vaccin adult age year
older
first phase trial enrol estim adult design
compar immun respons administr respons
vaccin pneumococc polysaccharid vaccin evalu
immunogen adult year age describ
safeti profil adult year old
januari announc initi pivot phase
clinic trial oral inhibitor treatment
patient moder sever alopecia areata chronic autoimmun skin
diseas caus hair loss scalp face bodi current
announc fda
accept file
applic nda
tafamidi
treatment
base two form
salt free acid
trial enrol estim patient double-blind
placebo control dose-rang studi evalu safeti
effect adult adolesc year older
greater scalp hair loss
januari announc fda accept file
compani new drug applic nda tafamidi treatment
transthyretin amyloid cardiomyopathi submit two nda base
two form tafamidi meglumin salt free acid
nda tafamidi meglumin mg capsul grant prioriti
review design prescript drug user fee act pdufa goal
date decis fda juli tafamidi free acid form
mg capsul undergo standard review pdufa goal date
decis fda novemb
free acid form bioequival mg tafamidi meglumin dose
administ four mg capsul pivot trial
develop patient conveni enabl singl capsul daili
compani announc posit top-lin result
phase studi evalu tanezumab mg mg patient
arm met three co-primari endpoint week demonstr
statist signific improv pain physic function
patient overal assess oa compar receiv placebo
tanezumab mg treatment arm met two three protocol-defin
co-primari efficaci endpoint compar placebo demonstr
statist signific improv pain physic function
patient overal assess oa statist differ
placebo patient enrol studi experienc inadequ pain
relief intoler least three differ class analges
averag oa six year
preliminari safeti data show tanezumab gener well toler
treatment period similarli low rate treatment
discontinu due advers event observ among patient take
tanezumab placebo trial also includ safeti follow-up
period total week observ
overal rapidli progress osteoarthr rpoa observ
tanezumab-tr patient observ placebo arm
ratio rpoa type acceler joint space narrow rpoa type
damag deterior joint consist ratio
previous report subcutan phase studi oa pain
one event osteonecrosi one event subchondr
insuffici fractur observ tanezumab-tr patient event
observ placebo arm rate total joint replac
similar across tanezumab treatment group placebo detail
efficaci safeti result studi submit futur
three protocol-
compar placebo
improv pain
physic function
assess oa
statist
differ placebo
enter definit
agreement gsk
two
compani agre
combin
new consum
oper global
gsk consum
start fiscal year began oper previously-
announc new commerci structur reorgan oper three
busi includ innov health busi unit except
consum healthcar well new hospit busi unit
commerci pfizer global portfolio steril inject anti infect
medicin also incorpor biosimilar portfolio oncolog
inflamm immunolog busi unit
upjohn global off-pat brand gener establish medicin
busi includ major off-pat solid oral dose
legaci brand includ lyrica lipitor norvasc viagra celebrex well
certain gener medicin allow busi act speed
flexibl distinct fully-ded manufactur market
regulatori except enabl function enhanc
autonomi posit oper true stand-alon busi within
consum healthcar includ pfizer over-the-count medicin
decemb enter definit agreement gsk
two compani agre combin respect consum
healthcar busi new consum healthcar joint ventur
oper global gsk consum healthcar name
exchang contribut consum healthcar busi
receiv equiti stake new compani gsk remain
new compani
upon close transact expect occur second
half subject customari close condit includ gsk sharehold
approv requir regulatori approv anticip deconsolid
consum healthcar busi begin receiv pro rata share
joint ventur earn dividend paid quarterli
right appoint three nine member joint
ventur board transact expect deliv peak cost
synergi slightli accret first three year
close transact
decemb board director declar
dividend compani common stock repres increas
compar compani dividend dividend payabl
march sharehold record close busi februari
addit board director also author new share
repurchas program util time januari pfizer
remain share repurchas author includ new
share repurchas program reflect share repurchas
date
januari
includ
new share
repurchas program
reflect
share repurchas
date
revenu guidanc
reflect
anticip
headwind product
recent lost
expect lose
shortli includ loe
lyrica
adjust sale
incom
effect tax rate adjust incom
guidanc reflect full year contribut revenu expens
consum healthcar revenu guidanc reflect
anticip headwind product recent lost
expect lose market exclus shortli includ loe lyrica
 june
also anticip neg impact unfavor chang
foreign exchang rate rel dollar compar actual fx rate
guidanc adjust dilut ep reflect anticip share repurchas
total dilut relat share-bas employe compens
program current expect off-set reduct share associ
share repurchas half
financi guidanc adjust incom /deduct adjust dilut
ep exclud impact realiz unreal gain loss
invest equiti secur
revenu increas oper reflect
continu growth sever import medicin vaccin emerg
market biosimilar growth off-set due neg
impact loe decreas legaci establish product portfolio
develop market steril inject portfolio
innov health segment grew oper led strength key
brand ibranc grew grew due intern develop
market xtandi gener revenu xeljanz revenu grew
due growth ra well new indic expect contribut
eliqui revenu grew
essenti health segment growth emerg market biosimilar
off-set lower revenu legaci establish product
portfolio develop market product suppli shortag steril
inject busi emerg market revenu busi grew
growth driver emerg market lipitor
increas norvasc grew steril inject increas
biosimilar busi grew
organ busi
biopharmaceut group science-bas innov medicin busi led
angela hwang upjohn off-pat brand gener medicin busi
headquart china bring icon brand
market around world consum health busi led
chri slager prepar becom part joint ventur
pfizer inc glaxosmithklin plc announc enter
agreement creat premier global consum healthcar compani robust
icon brand term transact receiv
equiti stake joint ventur entitl pro rata share
joint ventur earn dividend paid quarterli basi
return sharehold combin
dividend share repurchas remain commit deliv
attract sharehold return beyond
oper
growth sever
import medicin
market biosimilar
sharehold
combin
dividend share
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas compar
oper margin increas compar
net margin decreas compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc april
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale pfizer inc april
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset pfizer inc april
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer annual itemsquarterli item pfizer inc april
balanc item
outstand equival market debt common prefer purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free inc april
current price-to-earnings ratio fallen due declin stock price
quarter price-to-earnings shown huge fluctuat past due unsustain earn avg-
expect forward price-to-earnings
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock vanguard group inc capit world price row associ jp morgan america northern trust wellington manag compani geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut washington mutual investor fidel ishar incom fund america vanguard -valu select sector spdr fund-health competit
developmentspf secur exclus option acquir gene therapi compani vivet therapeuticsmarch vivet therapeut privat held gene therapi biotech compani dedic develop gene therapi treatment inherit liver disord high unmet medic need inc announc acquir equiti interest vivet secur exclus option acquir outstand share vivet collabor develop vivet proprietari treatment wilson diseas merck kgaa darmstadt germani pfizer announc discontinu phase javelin ovarian parp trial previous untreat advanc ovarian cancermarch kgaa darmstadt germani oper biopharmaceut busi emd serono us canada inc announc discontinu on-going phase javelin ovarian parp studi evalu efficaci safeti avelumab combin chemotherapi follow mainten therapi avelumab combin talazoparib poli adp-ribos polymeras parp inhibitor versu activ compar treatment-nav patient local advanc metastat ovarian cancer stage stage iv allianc notifi health author trial investig decis discontinu trial ochsner health system pfizer partner develop innov model clinic trialsfebruari orlean ochsner health system louisiana largest non-profit academ healthcar system inc enter multi-year strateg allianc develop innov model clinic trial partnership ochsner innov lab innovationochsn io partnership ochsner research explor way enhanc clinic trial experi eas particip clinic research patient healthcar profession pfizer receiv posit chmp opinion vizimpro dacomitinib first-lin treatment adult patient local advanc metastat non-smal cell lung cancer egfr-activ mutationsfebruari announc committe medicin product human use chmp european medicin agenc ema adopt posit opinion recommend vizimpro dacomitinib mg monotherapi grant market author european union eu first-lin treatment adult patient local advanc metastat non-smal cell lung cancer nsclc epiderm growth factor receptor egfr -activ mutat chmp opinion review european commiss ec inc april
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc april
consensu view analyst trend stock
compar
 average
forward price-to-earnings multipl
compar
 average
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonpfeindustri avg avgprice/earn yield inc april
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim
current qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate analyst recommend
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show huge fluctuat period dip januari
result
stock given rel flat return period
stock price show upward trend year volatil sinc august
rang stock stock gave return year
stock price volatil past year show upward trend past
stock surg novemb stock gave return past
pfizer revenu increas due growth key brand ibranc eliqui
prevnar partial off-set loss exclus product lower sale legaci establish
product develop market continu suppli shortag legaci hospira product recommend
hold rate base neg impact lyrica loe
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
